218 related articles for article (PubMed ID: 38381654)
1. Advanced Parkinson's disease treatment patterns in Italy: an observational study interim analysis.
Stocchi F; Barone P; Ceravolo R; De Pandis MF; Lopiano L; Modugno N; Padovani A; Pilleri M; Tessitore A; Zappia M
Ann Med; 2024 Dec; 56(1):2315226. PubMed ID: 38381654
[TBL] [Abstract][Full Text] [Related]
2. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
3. COMT Inhibitors in the Management of Parkinson's Disease.
Fabbri M; Ferreira JJ; Rascol O
CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
[TBL] [Abstract][Full Text] [Related]
4. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
5. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
6. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
7. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
[TBL] [Abstract][Full Text] [Related]
8. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates.
Metta V; Ibrahim H; Muralidharan N; Rodriguez K; Masagnay T; Mohan J; Lacsina A; Ahmed A; Benamer HTS; Chung-Faye G; Mrudula R; Falup-Pecurariu C; Rodriguez-Blazquez C; Borgohain R; Goyal V; Bhattacharya K; Chaudhuri KR
J Neural Transm (Vienna); 2024 Jan; 131(1):25-30. PubMed ID: 37798410
[TBL] [Abstract][Full Text] [Related]
9. The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study.
Ouma S; Fukae J; Fujioka S; Yamamoto S; Hatano T; Yoritaka A; Okuma Y; Kashihara KI; Hattori N; Tsuboi Y
Intern Med; 2017; 56(15):1961-1966. PubMed ID: 28768964
[TBL] [Abstract][Full Text] [Related]
10. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
[TBL] [Abstract][Full Text] [Related]
11. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
14. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
Elmer LW
Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
[TBL] [Abstract][Full Text] [Related]
15. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
17. [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
Woitalla D; Krüger R; Lorenzl S; Müller T; Oelwein G; Storch A; Wolz M; Wüllner U
Fortschr Neurol Psychiatr; 2020 Sep; 88(9):620-633. PubMed ID: 32588409
[TBL] [Abstract][Full Text] [Related]
18. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
Katsaiti I; Nixon J
J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease: medical treatment of moderate to advanced disease.
Suchowersky O
Curr Neurol Neurosci Rep; 2002 Jul; 2(4):310-6. PubMed ID: 12044250
[TBL] [Abstract][Full Text] [Related]
20. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Cattaneo C; Sardina M; Bonizzoni E
J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
